Health Care

Tom Farley: tip of the spear in Philly's fight against opioid crisis

Tom Farley – Samantha Madera/City of Philadelphia

Tom Farley – Samantha Madera/City of Philadelphia

In the world of Philadelphia bureaucrats, Dr. Tom Farley keeps an unusually low profile, despite his very visible role as the city's commissioner of the Department of Public Health.

Back in January, the Tulane-educated physician joined nearly 400 workers for the city’s annual overnight count of the city’s homeless population. He toured the darkened streets of Kensington with a small crew of Prevention Point staffers. A wiry 62-year-old with a clinician’s unflappable demeanor, Farley spent the evening on the sidelines, speaking only to ask questions from harm reduction experts and drug users living on the streets. “I had no idea he was the health commissioner until hours later,” recalled a volunteer who worked alongside him that night.

With similar discretion, Farley has spent the last two years in Philadelphia tending to the woes of a deeply unhealthy city. Chronic obesity, high smoking rates, sexually transmitted diseases, cockroach-plagued restaurants – the purview of his 1,200-employee department is vast and its influence somewhat limited.

But in the world of public health, success and failure are measured in preventable deaths. And for that reason, Farley has become a key figure in the city’s battle against the overdose crisis, which claimed more than 2,100 lives between 2016 and 2017 in the doctor’s first two years on the job.

Under his watch, the Department of Public Health’s fledgling opioid surveillance team has begun collecting reams of data using every source within reach, from the bodies at the Medical Examiner’s Office to the opioid users on the streets of Kensington. Farley spends a large part of his opioid-prevention budget on naloxone, an opioid-overdose reversing agent, and has employed mass media campaigns to encourage all Philadelphians to carry the life-saving drug at all times. He was also an early champion of the city’s controversial push for Comprehensive User Engagement Sites, facilities where people can safely use drugs while having access to treatment and other social services.

“The scientific evidence says this is going to save lives, this is going to help people get into treatment and this is going to help community problems associated with drug use,” Farley says, seated in his downtown office in early May. “It’s got everything going for it even if your initial reaction is negative.”

Sources in the harm reduction community say he has been instrumental in turning CUES skeptics into believers. One harm reduction official said Farley’s direct, data-driven approach helped change Philadelphia Police Commissioner Richard Ross’ mind on the topic. Farley denies it, deferring credit to the Vancouver police chief: “His initial reaction [with me] was not very positive.”

But Farley knows the limits of what education can do. An author of two books, he has examined how the education model has failed to solve public health epidemics. (Just look at the once-popular DARE Program, which scientists have since proven did little to quell drug use in adolescents.) For Farley, the challenge is not changing people’s behavior when it comes to deadly narcotics.

“I came from a world where people thought that humans acted very rationally,” Farley says. “But the data does not support that – because no one wants to be overweight and yet everyone is becoming more and more overweight. So what drives human behavior as it relates to health and how can we change that? We do it by changing the world around us. That’s the source of the problem and that’s the source of the solution.”

On a Wednesday morning in early May, Farley meets with his opioid surveillance team, which consists of program manager Kendra Viner, policy analyst Jeff Hom and deputy health commissioner Caroline Johnson. It is a new unit with a shoestring budget, a large chunk of which is spent on getting naloxone into the hands of those who need it. (“It’s scandalous how much it costs at a time when people are dying,” Farley says, of the drug’s $70 per-dose price tag.)

Beyond naloxone, though, Farley’s number one priority is to get local doctors to prescribe fewer painkillers. The health department cannot enforce prescriptions, but by using state monitoring data, Farley and his team reach out to doctors themselves and try to make an impact. Some epidemiologists say subscription monitoring is an overhyped measure that has little effect on opioid deaths, but to Farley, it’s the best long-game tool on his belt to reduce Philly’s addicted population.

“Prescribing less is the best long-term approach,” Farley says. “Stopping fatal overdoses is a stop-gap approach until we can have fewer people addicted in the first place.”

When Mayor Jim Kenney tapped Farley as the city’s top public health official in 2016, the overdose crisis was quickly erupting from nascent concern to full-blown national epidemic. With deadly synthetic fentanyl flooding the illegal drug market, that year ended with 907 unintentional overdose fatalities citywide. Last year, when fatalities climbed by more than a third to 1,217, Philadelphia ranked the highest overdose death rate among the 44 cities with a population over 1 million. In 1994, AIDS deaths in the city peaked at 935. “We’ve already surpassed that now,” Farley notes.

Farley had served as New York City’s health commissioner under then-Mayor Michael Bloomberg, where he made waves for his unconventional public health initiatives – some well-received, some not. Tackling the city’s tobacco and obesity rates, he was an early booster of smoking bans and he went to war against trans fats. As an advisor to his predecessor, Thomas Friedman, Farley prepared a “white paper” proposing to shut down the city’s gay bathhouses to curb sexually transmitted diseases. The plan was scrapped, but Farley continued to face criticism over the years from the city’s LGBT community.

In Philadelphia, he has avoided the perception of being out of touch. He became a natural booster of Kenney’s soda tax. And while he manages a litany of the health department’s other duties, the opioid epidemic has brought unprecedented attention to his department, despite its finite resources.

At the meeting, the opioid team discusses how to get naloxone distribution into the city’s methadone clinics. They run through a wish-list of datasets to track down, share concerns about stigma in treatment, and discuss outreach to overdose hotspots in South and Northeast Philadelphia that receive far less outreach than hard-hit Kensington. Eventually, CUES comes up.

Once poised to make history by opening the first safe consumption site in the U.S., critics say Philadelphia has been slow to follow through on the proposal while people continue to die at an alarming rate. Farley offers no exaggerate hopes for the facility.

“The estimate an expert came up with at our request is that CUES would save 25 to 75 lives per year, which you could say is so small it’s not worth doing or you could say, gosh, one of those people could be my daughter,” Farley says. “I think it’s worth it.”

Farley says there is little he can do beyond presenting other stakeholders with the science in favor of CUES. The site requires private funding, and Farley, an outsider to Philadelphia’s monied philanthropists, can do little to help bring in dollars. “I’m a terrible fundraiser,” he says.

The opioid overdose epidemic is still a relatively new phenomenon – one that still lacks the investment it needs, both in expanding treatment and in identifying solutions. Meanwhile, Farley has an entire department to run, from overseeing government-run health clinics (Philly is one of few cities that do this) to health inspections at city restaurants.

On a Thursday morning, he meets with Coleman Terrell, the director of the health department’s AIDS Activities Coordinating Office, or AACO. They run through the unit’s performance metrics for the most recent quarter – a granular survey of everything happening in sexually transmitted disease across the city. It is a robust operation in comparison to the department’s opioid surveillance. AACO can track everything from infection rates to the gaps between HIV patient visits to city health clinics, and each metric has a target goal to achieve.

“We didn’t have any of this back then,” Farley says. “And we don’t have anything like this now for the opioid crisis.”

When Farley took over the department, the infrastructure was already in place to increase monitoring for certain conditions. He noticed city medical providers were not asking HIV patients about condom usage, and promptly made it a mandatory metric.

Of course, data collection is only one part of fighting a crisis, but it’s necessary to craft more effective policy – and to monitor what’s working and what isn’t within a tangled bureaucratic web. The health department works closely alongside the Managing Director’s Office (which handles policy changes), the Department of Behavioral Health (addiction treatment) and other city agencies to combat the crisis.

“We’re just one player of many in city government working on this,” he says. “But we do have specific areas of expertise where we can make a difference.”

Data is one of those areas, Farley believes, and given more resources they can collect more of it and in higher quality. Their recent survey of city drug users offers evidence some say indicates naloxone's widespread distribution is stopping untold numbers of overdoses from turning fatal on the streets of Kensington.

“We had to set up an entire new program to deal with AIDS, and it’s worked,” Farley says. “It’s still very exciting to see the number of HIV infections continue to go down. I hope I live long enough to see them go down to zero, and I may, and so in a way that’s a model [for the opioid crisis]. Given enough resources and creative thinking, we can respond to these crises and save a lot of lives. In the meantime, it’s an ongoing tragedy.”

X
This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We also share information about your use of our site with our social media, advertising and analytics partners. Learn More / Do Not Sell My Personal Information
Accept Cookies
X
Cookie Preferences Cookie List

Do Not Sell My Personal Information

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link.

Allow All Cookies

Manage Consent Preferences

Strictly Necessary Cookies - Always Active

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data, Targeting & Social Media Cookies

Under the California Consumer Privacy Act, you have the right to opt-out of the sale of your personal information to third parties. These cookies collect information for analytics and to personalize your experience with targeted ads. You may exercise your right to opt out of the sale of personal information by using this toggle switch. If you opt out we will not be able to offer you personalised ads and will not hand over your personal information to any third parties. Additionally, you may contact our legal department for further clarification about your rights as a California consumer by using this Exercise My Rights link

If you have enabled privacy controls on your browser (such as a plugin), we have to take that as a valid request to opt-out. Therefore we would not be able to track your activity through the web. This may affect our ability to personalize ads according to your preferences.

Targeting cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Social media cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

If you want to opt out of all of our lead reports and lists, please submit a privacy request at our Do Not Sell page.

Save Settings
Cookie Preferences Cookie List

Cookie List

A cookie is a small piece of data (text file) that a website – when visited by a user – asks your browser to store on your device in order to remember information about you, such as your language preference or login information. Those cookies are set by us and called first-party cookies. We also use third-party cookies – which are cookies from a domain different than the domain of the website you are visiting – for our advertising and marketing efforts. More specifically, we use cookies and other tracking technologies for the following purposes:

Strictly Necessary Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Functional Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Performance Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Social Media Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Targeting Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.